MANP
/ E-Star BioTech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 07, 2025
BOLD-HTN: To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: E-Star BioTech, LLC | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2025 ➔ Jul 2026
Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
February 05, 2025
E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension
(GlobeNewswire)
- "E-Star BioTech, LLC...today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension."
Trial status • Hypertension
1 to 2
Of
2
Go to page
1